Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

6.60USD
16 Feb 2018
Change (% chg)

$0.63 (+10.55%)
Prev Close
$5.97
Open
$6.09
Day's High
$6.62
Day's Low
$6.05
Volume
268,529
Avg. Vol
160,681
52-wk High
$15.51
52-wk Low
$5.02

Select another date:

Tue, Jan 30 2018

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

Bellicum's cancer drug trials on clinical hold, shares tumble

Jan 30 Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

BRIEF-Bellicum Enters Into Agreement With Oxford Finance To Borrow $35 Mln - SEC Filing

* BELLICUM PHARMACEUTICALS SAYS ENTERED INTO AGREEMENT WITH OXFORD FINANCE LLC TO BORROW $35.0 MILLION IN A SINGLE TERM LOAN - SEC FILING Source text: (http://bit.ly/2BhY3X0) Further company coverage:

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​

Select another date: